Clinical Trials Logo

Ototoxicity clinical trials

View clinical trials related to Ototoxicity.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05730283 Not yet recruiting - Clinical trials for Ototoxicity, Drug-Induced

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test the effectiveness of the study drug, ORC-13361, in preventing hearing loss in patients with NTM infection who are undergoing treatment with IV amikacin therapy. The main question this study aims to answer is: - Is ORC-13661 effective for preventing or lessening hearing loss induced by amikacin treatment? - Is ORC-13661 effective for preventing or lessening other measures of hearing impairment? Participants will be asked to take a study drug while they are being treated with IV amikacin. Participants will take study drug for 90 days or until the end of their amikacin treatment, whichever comes first. During this time, researchers will gather clinical data on the participants' health. Researchers will compare three groups - two groups taking different doses of the study drug and one group taking a placebo drug - to see if dose of drug has any effect on preventing hearing loss. A placebo is a look-alike substance that contains no active drug.

NCT ID: NCT01451853 Not yet recruiting - Lung Cancer Clinical Trials

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Start date: January 15, 2018
Phase: Phase 2
Study type: Interventional

Chemotherapy treatment with platinum based agents is well noted to cause ototoxicity. It is the objective of this study to determine the safety and efficacy of SPI-1005 at three dose levels when delivered orally twice daily for 3 days, surrounding each cycle of platinum chemotherapy in head and neck or non-small cell lung cancer patients to prevent and treat chemotherapy induced hearing loss and tinnitus.

NCT ID: NCT01285674 Not yet recruiting - Ototoxicity Clinical Trials

Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin.

Start date: January 2011
Phase: N/A
Study type: Interventional

In this study we will aim to determine if cisplatin ototoxicity can be prevented by intratympanic administration of corticosteroids.

NCT ID: NCT00578760 Not yet recruiting - Hearing Loss Clinical Trials

Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?

Start date: February 2008
Phase: N/A
Study type: Interventional

Aspirin (ASA) has been shown, in an animal model, to attenuate the ototoxic properties of cisplatin. The researchers plan to investigate this in patients undergoing cisplatin chemotherapy. The researchers hypothesise that low-dose aspirin can prevent cisplatin induced ototoxicity in the clinical setting.